Project Details
Description
Biogen Tysabri Contract: Anti-T cell therapy for Multiple System Atrophy Biogen Tysabri Contract: Anti-T cell therapy for Multiple System Atrophy
| Status | Finished |
|---|---|
| Effective start/end date | 4/18/22 → 12/31/22 |
Funding
- INDUSTRY: Domestic Company: $89,759.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.